Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
361-380 of 3,900 trials

Iron Supplement for Better Recovery After Major Surgery

We are studying whether Ferric Carboxymaltose can improve recovery and reduce complications for patients who have undergone major surgeries with significant blood loss. This trial will help us understand its impact on anemia and overall quality of life.

Anemia>2 yearsConfirmation phase (III)Investigational MedicinesCardiologyGastroenterologyHematology

Aggressive B-cell Non-Hodgkin Lymphoma: Odronextamab Study

We are studying how well odronextamab works compared to standard treatments for adults with previously treated aggressive B-cell non-Hodgkin lymphoma. The trial will also look at safety and how treatment affects daily life.

B-Cell Non-Hodgkin's Lymphoma1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Herpes Zoster Vaccine for Immunocompromised Kids

We are studying a new vaccine for children aged 1 to 17 who have had kidney transplants. The trial will help us understand its safety and how well it triggers an immune response.

Prevention of Shingles in Immunocompromised Children1-2 yearsEfficacy phase (II)No PlaceboCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicinePediatrics

Diffuse Large B-Cell Lymphoma: Odronextamab vs. Rituximab

We are studying how well odronextamab combined with chemotherapy works compared to rituximab with chemotherapy in patients who have not yet received treatment for diffuse large B-cell lymphoma. The trial aims to evaluate safety and effectiveness in this patient group.

Diffuse Large B-cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Primary Central Nervous System Lymphoma: MTR² Treatment Study

We are studying a new combination of medications for patients with primary central nervous system lymphoma who cannot receive intensive therapies. The goal is to see if this treatment is effective and safe, and how it affects quality of life.

Primary Central Nervous Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyNeurology

Actinic Keratosis: Sinecatechins Ointment Study

We are studying a green tea extract ointment for adults with actinic keratosis on the scalp and face. The goal is to see if it clears skin lesions better than a placebo and to assess its safety.

Actinic Keratosis3-6 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

Melanoma Treatment: Fianlimab and Cemiplimab Study

We are investigating whether combining fianlimab and cemiplimab is safer and more effective than cemiplimab alone for adults with resectable stage III or IV melanoma. This study aims to see how well these treatments work before surgery.

Malignant Melanoma>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

B-Cell Malignancies: CAR-T Cell Therapy Study

We are testing a new CAR-T cell treatment for patients with relapsed and refractory B-cell cancers. The goal is to find a safe dose and understand how well it works.

Diffuse Large B-Cell LymphomaMultiple Myeloma1-2 yearsSafety phase (I)HematologyOncology

Idiopathic Inflammatory Myopathy: Efgartigimod Treatment

We are studying the long-term safety and effects of a new injection for adults with active idiopathic inflammatory myopathy. This research aims to see if it can help reduce steroid use and improve health outcomes.

Active Idiopathic Inflammatory Myopathy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Fibrolamellar Hepatocellular Carcinoma: DNAJB1-PRKACA Vaccine

We are testing a new peptide vaccine for patients with fibrolamellar hepatocellular carcinoma and other tumors with a specific genetic fusion. This study aims to see if it works better when combined with immune checkpoint therapy.

Tumor with DNAJB1-PRKACA FusionFibrolamellar Hepatocellular CarcinomaSafety phase (I)HepatologyOncology

Favipiravir: High Dose Tolerance Study

We are evaluating how well healthy volunteers tolerate a high dose of favipiravir. This study will help us understand the drug's effects on the body.

Healthy Volunteers>2 yearsSafety phase (I)Infectious Diseases

Wilson Disease: UX701 Gene Therapy Study

We are evaluating a new gene therapy for adults with Wilson disease to see if it safely helps manage copper levels in the body. The study will also look at how it affects the need for current medications and overall liver health.

Wilson's Disease1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInfectious DiseasesInternal Medicine

Pulmonary Sarcoidosis: XTMAB-16 Treatment Study

We are testing a new treatment called XTMAB-16 for people with pulmonary sarcoidosis to see if it can safely reduce the need for corticosteroids. This study will help determine the best dose and assess its effectiveness.

Pulmonary Sarcoidosis3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsInvestigational MedicinesInternal MedicinePulmonology

Deucravacitinib for Inflammatory Skin Conditions

We are studying a new treatment for adults with inflammatory epidermal genodermatoses, including severe forms of ichthyosis and epidermolysis bullosa. The trial will evaluate how well it works and its safety over time.

Epidermolysis BullosaCongenital Ichthyosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDermatology

HIV-1 Treatment: Long-Acting Cabotegravir and Rilpivirine for Older Adults

We are studying a new long-acting treatment for people aged 60 and older living with HIV-1. The goal is to see if it effectively controls the virus and how it affects overall health.

HIV-1>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Chemotherapy-Induced Polyneuropathy: Aconite Pain Oil Study

We are studying whether Aconite Pain Oil can help prevent and reduce symptoms of chemotherapy-induced polyneuropathy in cancer patients. The goal is to improve quality of life and manage symptoms during treatment.

Chemotherapy-Induced Polyneuropathy>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesNeurologyOncology

Kidney Stones: Furosemide Injection Study

We are investigating whether a Furosemide injection after kidney stone removal improves the chances of being stone-free and reduces the risk of infections. This study involves patients undergoing flexible ureteroscopy for kidney stones.

Kidney Stones>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementUrology

ADHD Treatment: Dexamfetamine Formulations

We are studying two types of dexamfetamine sulfate in adults with ADHD to see if they are more effective than a placebo. The trial will also evaluate the safety of these medications.

Attention Deficit Hyperactivity Disorder (ADHD)6-12 monthsConfirmation phase (III)11-15 visitsStandard MedicinesNeurologyPsychiatry

Mantle-Cell Lymphoma: KTE-X19 CAR-T Cell Therapy

We are studying a new CAR-T cell therapy for patients with relapsed or refractory mantle-cell lymphoma who responded partially to ibrutinib. The trial aims to evaluate its effectiveness and safety in improving patient outcomes.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Propionic Acidemia: mRNA-3927 Treatment Study

We are investigating the safety and effectiveness of mRNA-3927 in individuals with propionic acidemia. The study aims to see if this treatment can reduce serious health events related to the condition.

Propionic AcidemiaSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyInternal Medicine